Catherine Kelly, MD
Family Medicine · Fayetteville, NCNPI 1871584425
Payments from drug & device makers
Across 144 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$286
- Novo Nordisk$271
- Pfizer$245
- Boehringer Ingelheim$243
- Astellas Pharma US Inc$230
- Abbott$182
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,43195%
- Education$1074%
- Gifts$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $286 |
| Novo Nordisk | 15 | $271 |
| Pfizer | 14 | $245 |
| Boehringer Ingelheim | 13 | $243 |
| Astellas Pharma US Inc | 8 | $230 |
| Abbott | 10 | $182 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $132 |
| AstraZeneca | 9 | $121 |
| Amgen | 7 | $104 |
| Lilly USA, LLC | 5 | $71 |
| GSK | 4 | $58 |
| Amarin Pharma, Inc. | 3 | $52 |
| Bayer | 2 | $51 |
| Mylan Specialty L.p. | 3 | $45 |
| Boston Scientific | 1 | $42 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Eisai Inc. | 2 | $27 |
| Exact Sciences | 1 | $25 |
| Merck | 1 | $23 |
| Dexcom, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| Bausch Health US, LLC | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
| Mirati Therapeutics, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
| Novartis | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
| Seqirus USA Inc | 1 | $11 |
How this compares
$2,552 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $104,185 |
| JardianceEmpagliflozin | 105 | $100,683 |
| EliquisApixaban | 84 | $95,011 |
| RybelsusSemaglutide | 17 | $28,813 |
| XareltoRivaroxaban | 20 | $20,667 |
| MyrbetriqMirabegron | 32 | $18,965 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $15,607 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 66 | $14,906 |
| Victoza 3-PakLiraglutide | 16 | $14,730 |
| LinzessLinaclotide | 13 | $10,911 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 33 | $10,723 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $10,444 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 66 | $10,303 |
| Victoza 2-PakLiraglutide | 16 | $9,328 |
| VascepaIcosapent Ethyl | 11 | $5,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $271 | $132,99985 claims |
| Boehringer IngelheimJardiance | $243 | $100,683105 claims |
| PfizerEliquis | $245 | $95,01184 claims |
| GSKShingrix, Arexvy | $58 | $25,62999 claims |
| Astellas Pharma US IncMyrbetriq | $230 | $18,96532 claims |
| AbbVieLinzess, Synthroid | $286 | $12,39431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Fayetteville
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.